Exchange: NYSEMkt·Updated 08:38 PM EST
TOVX logo

TOVX Theriva Biologics Inc

$0.14
$0.00
(0.00%)
Overnight
Prev Close $0.14
Reported EarningsNov 12
Mkt Cap$6.61M
Vol820,608.00

About TOVX

Theriva Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-020 and SYN-004. SYN-020 is intended to prevent the antibiotic-mediated microbiome damage, C. difficile infections (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR) and acute graft-versus-host disease (aGVHD) in allogeneic HCT recipients. SYN-004 is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer on January 8, 2001 and is headquartered in Rockville, MD.
49

Neutral Sentiment

How do you feel about TOVX?

grocklein
$TOVX They received $350K to offload all the future development costs related to SYN-004, but kept the potential future upside of $91M in milestone payments and up to $250M in royalties. Seems pretty prudent given their constrained finances. They still get a decent shot on goal with SYN-004 without having to pay for it.
6
Bigmike1987
$TOVX imagine being the guy that was incharge of this company running it into the ground from hundreds of dollars per share down to a few pennies honestly how you can pullup outside that buisness each day and stroll in the door id be hiding under a rock with shame
5
BreakoutBullz
$TOVX Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc
1
Chicagoteacher
$TOVX I was hoping that this would help me financially. I don't have much in the stock, but I thought it had a chance. Ok well. We're all Charlie Brown with this stock.
3
Thess5
$TOVX 😂🍳. Five company name changes. 5 or more reverse splits. Diluted a dozen times. All under Shallcross. The name suited him. A just punishment 🧐 2020 filings and quarterly earnings reports were red flags. Saw the lies then. Glad I got out with small loss. Made back with some of the pumps over the years. The wealthy like him are 99.999% protected due to wealth, and who they know. At this point only a R/S can elevate the PPS. Probably going below .15 sooner than later.
3
jtrades90
$TOVX feels like it may be dead, but the sell of SYN-004 makes me believe it’s not. Compliance is .20 which is a tough hill to climb back to without news as it continues to bleed out
2
BearRifle
$TOVX I'm ok with this, Shallcross. Good move selling SYN004 for 350K and $91 Million in milestones. This is leadership. Now find us a big partner for the central pipeline, please and thank you!
2
sSwSs
$TOVX — Theriva Biologics' recent analyses covered its divestiture of SYN-004, clinical trial updates for VCN-01, and ongoing financial performance. Recent analyses for Theriva Biologics (TOVX) examined the company's financial performance, including revenue and net losses over several years, alongside technical trading indicators suggesting bearish momentum. The reports also detailed recent corporate actions such as the sale of its SYN-004 portfolio and clinical trial updates for VCN-01.
1
PopChart
$TOVX – Theriva received a $350,000 upfront payment at closing and is eligible for up to $91 million in regulatory and sales milestones, along with low single-digit royalties on net product sales – – Biossil to assume all responsibility and costs for future development and commercialization of the antibiotic-degrading enzyme portfolio –
1
Stock_Catcher
$TOVX Theriva™ Biologics Announces Sale of SYN-004 (ribaxamase) and Related Antibiotic-Degrading Enzyme Portfolio to Biossil Labs Inc.
1
louter_genieten
$TOVX A summary and a question what to do? So the non-oncology pipelines are gone (sold) there is a lot of accounts receivable if those products succeed. The stroma degrading adeno virus helps against multiple types of cancers (head&neck, blastoma and pancreas). The improved regimen of multiple doses currently tested extra in phase 2b improves the SoC of pranceas cancer (the most deadly). The working mechanism is published in nature medicine a couple of weeks ago. The stockprice is a warzone dictated by those who gamble on cash left, (past) dillution and (past) name changes. They have there algo's fixed on bankruptcy and will do anything to make it work. I still have a position and nobody cared to lend it, though the price crashed.

Advertisement|Remove ads.